The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | The evolving landscape of functional imaging in multiple myeloma
Marco Talarico, MD, University of Bologna, Bologna, Italy, comments on the evolving landscape of functional imaging in multiple myeloma. He highlights the limitations of FDG PET/CT and discusses the potential of alternative techniques, which have shown value at diagnosis and in prognostication. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The main functional imaging technique in multiple myeloma has always been FDG PET/CT. Since it is considered a standard technique at diagnosis, as it can detect the presence of osteolytic lesions and thanks to its CT scan, and it is necessary in the response assessment for the assessment of the so-called imaging MRD. This is the standard technique. However, in recent years, novel functional imaging techniques have been proposed, particularly the use of alternative radiotracers in PET, which are now on study, since FDG has about 10-15% of false negative and false positive scans...
The main functional imaging technique in multiple myeloma has always been FDG PET/CT. Since it is considered a standard technique at diagnosis, as it can detect the presence of osteolytic lesions and thanks to its CT scan, and it is necessary in the response assessment for the assessment of the so-called imaging MRD. This is the standard technique. However, in recent years, novel functional imaging techniques have been proposed, particularly the use of alternative radiotracers in PET, which are now on study, since FDG has about 10-15% of false negative and false positive scans. But we have no standardized data regarding alternative radiotracers right now. And the use of functional MRI scans has also been proposed. We have to consider that conventional MRI is a significant tool at diagnosis and in staging, but it has not been proven prognostic in response assessment in the French IFM 2009 trial. However, the use of functional MRI scans has been proposed, particularly the use of diffusion-weighted MRI, which we are using in our study, since the achievement of a response by this technique has been proven prognostic in both retrospective and in prospective experiences. The use of further functional MRI scans is ongoing, particularly the dynamic contrast-enhanced MRI, and today several centers are using a combination of PET and MRI, the so-called PET MRI.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
